Phase I single-dose trial of ICA 105665 in male volunteers.
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2009
At a glance
- Drugs ICA 105665 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Neusentis
- 25 Nov 2009 Results will be presented at the 63rd Annual Meeting of the American Epilepsy Society.
- 08 May 2008 Status changed from recruiting to completed, as reported by Icagen.
- 13 Sep 2007 New trial record.